|
Chief Scientist at the NCI to speak at 3rd Imaging in Drug Development conference - March 17-18, San Diego
Dr. Hisataka Kobayashi, Chief Scientist of Molecular Imaging at the National Cancer Institute will speak at GTCbio’s 3rd Imaging in Pre-clinical & Clinical Drug Development conference March 17-18, 2008 in San Diego, CA.
 Print View
January 24, 2008 (FPRC) -- Dr. Hisataka Kobayashi, Chief Scientist of Molecular Imaging at the National Cancer Institute will speak at GTCbio’s 3rd Imaging in Pre-clinical & Clinical Drug Development conference March 17-18, 2008 in San Diego, CA.
Dr. Kobayashi will discuss environment sensitive "smart" imaging probe for super-specific cancer cell detection.
A major goal of targeted molecular imaging of cancer is to improve the sensitivity and specificity so that even minimal clusters of aberrant cells can be detected in vivo thus permitting earlier intervention. Because the target?in this case a tumor?is only detectable in reference to its background, the most common strategies to improve imaging involve increasing the signal from the target tissue while assuming the background signal will remain constant. One strategy to achieve highly specific and sensitive monitoring of targeted cancer cells, would be to combine the desirable target binding characteristics of a monoclonal antibody with a signaling molecule, which is only activated within cancer cells, thus reducing background signal. Herein, we propose a fluorescence-based activatable “smart” strategy of maximizing target signal while minimizing or eliminating the background signal. With this activatable imaging strategy, we have designed and synthesized a series of activatable “smart” cancer-targeting probes, and achieved target specific cancer imaging with extremely low background signal while clearly depicting peritoneally disseminated micro-metastasis and lung micro-metastasis with extremely high sensitivity and specificity.
Dr. Kobayahsi’s presentation will look at new cancer-cell specific molecular imaging strategy for performing super-specific cancer detection, the design and synthesis of fluorescence-based activatable “smart” probes for the cancer molecular imaging, the detection of micro-metastasis of cancer with super-high sensitivity, practical clinical application for endoscopy-based imaging or surgery-assistance, and possible real-time specific monitoring of viable cancer cells under treatment
Presenting organizations at the 3rd Imaging in Pre-clinical & Clinical Drug Development conference include GlaxoSmithKline, Pfizer, Abbott, Schering-Plough, Bristol-Myers Squibb, GE Healthcare, Siemens, NIH, UCLA, 3-D Imaging, and more.
The 3rd Imaging in Pre-clinical & Clinical Drug Development conference features presentations on novel imaging methods and technology, imaging in drug development and therapy, imaging applications in CNS, imaging applications in oncology and imaging applications in the cardiovascular system. For more information, visit www.gtcbio.com.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, customerservices@gtcbio.com
Send an email to Rania Hafez of GTCbio
626)256-6405 x 102
Keywords:
Imaging, Clinical Drug Development
|
